Profile data is unavailable for this security.
About the company
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. It has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-102, RT-105, RT-111 and RT-110. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200uL in liquid form with high bioavailability.
- Revenue in USD (TTM)0.00
- Net income in USD-28.17m
- Incorporated2021
- Employees140.00
- LocationRani Therapeutics Holdings Inc2051 Ringwood AvenueSAN JOSE 95131United StatesUSA
- Phone+1 (408) 457-3700
- Fax+1 (302) 655-5049
- Websitehttps://www.ranitherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anixa Biosciences Inc | 0.00 | -12.36m | 102.97m | 4.00 | -- | 4.73 | -- | -- | -0.3906 | -0.3906 | 0.00 | 0.6772 | 0.00 | -- | -- | 0.00 | -50.54 | -59.69 | -52.50 | -62.61 | -- | -- | -- | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
| Context Therapeutics Inc | 0.00 | -30.15m | 104.25m | 5.00 | -- | 1.24 | -- | -- | -0.9117 | -0.9117 | 0.00 | 1.12 | 0.00 | -- | -- | 0.00 | -55.16 | -- | -58.90 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
| Medicinova Inc | 0.00 | -10.29m | 104.47m | 13.00 | -- | 1.90 | -- | -- | -0.2099 | -0.2099 | 0.00 | 1.12 | 0.00 | -- | -- | 0.00 | -16.31 | -15.36 | -17.03 | -15.90 | -- | -- | -- | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
| Avalo Therapeutics Inc | 820.00k | -8.14m | 105.29m | 19.00 | -- | 4.65 | -- | 128.40 | -10.96 | -10.96 | 0.1976 | 2.35 | 0.0128 | -- | 0.6467 | 43,157.89 | -12.46 | -99.64 | -26.07 | -154.42 | 182.20 | 84.69 | -970.49 | -613.58 | -- | -6.69 | 0.00 | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -17.69m | 105.37m | 9.00 | -- | 17.73 | -- | -- | -0.1726 | -0.1726 | 0.00 | 0.0537 | 0.00 | -- | -- | 0.00 | -91.52 | -58.16 | -138.98 | -75.36 | -- | -- | -- | -- | -- | -- | 0.0427 | -- | -- | -- | -14.90 | -- | -- | -- |
| CAMP4 Therapeutics Corp | 350.00k | -49.71m | 105.52m | 58.00 | -- | -- | -- | 301.49 | -2.55 | -2.55 | 0.0179 | 0.7707 | -- | -- | -- | 5,468.75 | -- | -- | -- | -- | -- | -- | -14,203.71 | -- | -- | -- | 0.0221 | -- | -- | -- | -11.54 | -- | -- | -- |
| Inovio Pharmaceuticals Inc | 203.41k | -112.88m | 105.67m | 122.00 | -- | 1.44 | -- | 519.52 | -4.49 | -4.49 | 0.008 | 2.82 | 0.0014 | -- | 0.2184 | 1,667.30 | -75.21 | -59.52 | -96.91 | -71.29 | -- | -- | -55,491.91 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
| Karyopharm Therapeutics Inc | 148.44m | -87.48m | 105.89m | 325.00 | -- | -- | -- | 0.7134 | -0.7906 | -0.7906 | 1.17 | -1.27 | 0.6462 | 1.58 | 4.26 | 456,744.60 | -38.08 | -53.02 | -52.09 | -65.85 | 95.85 | 97.18 | -58.93 | -125.15 | 2.93 | -5.25 | 2.53 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
| Monopar Therapeutics Inc | 0.00 | -6.47m | 106.08m | 10.00 | -- | 14.32 | -- | -- | -1.99 | -1.99 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -88.32 | -54.07 | -112.04 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
| INmune Bio Inc | 42.00k | -41.27m | 107.98m | 11.00 | -- | 2.79 | -- | 2,570.95 | -2.18 | -2.18 | 0.0022 | 1.74 | 0.0007 | -- | 0.0228 | 3,818.18 | -71.48 | -37.82 | -94.55 | -41.86 | -- | -- | -98,266.66 | -14,901.03 | -- | -34.08 | 0.0606 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Coya Therapeutics Inc | 9.55m | -10.70m | 108.60m | 8.00 | -- | 3.09 | -- | 11.37 | -0.6928 | -0.6928 | 0.687 | 2.10 | 0.4027 | -- | -- | 1,194,290.00 | -45.10 | -- | -49.39 | -- | -- | -- | -111.98 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -28.17m | 111.50m | 140.00 | -- | 35.95 | -- | -- | -1.06 | -1.06 | 0.00 | 0.0579 | 0.00 | -- | -- | 0.00 | -96.37 | -- | -165.17 | -- | -- | -- | -- | -- | -- | -16.57 | 0.8306 | -- | -- | -- | -11.06 | -- | -- | -- |
| Pyxis Oncology Inc | 16.15m | -57.36m | 112.98m | 54.00 | -- | 0.735 | -- | 7.00 | -1.05 | -1.05 | 0.2977 | 2.59 | 0.0845 | -- | -- | 322,920.00 | -30.03 | -- | -34.41 | -- | 97.06 | -- | -355.24 | -- | -- | -- | 0.0008 | -- | -- | -- | 38.87 | -- | -- | -- |
| Alto Neuroscience Inc | 0.00 | -57.45m | 116.19m | 88.00 | -- | 0.7042 | -- | -- | -2.42 | -2.42 | 0.00 | 6.12 | 0.00 | -- | -- | 0.00 | -46.93 | -- | -51.10 | -- | -- | -- | -- | -- | -- | -- | 0.0649 | -- | -- | -- | -31.02 | -- | -- | -- |
| Outlook Therapeutics Inc | 0.00 | -94.05m | 118.99m | 24.00 | -- | -- | -- | -- | -8.12 | -8.12 | 0.00 | -3.57 | 0.00 | -- | -- | 0.00 | -205.48 | -214.69 | -- | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.89 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
| Repare Therapeutics Inc | 66.52m | -84.05m | 119.46m | 179.00 | -- | 0.6828 | -- | 1.80 | -2.00 | -2.00 | 1.56 | 4.12 | 0.270 | -- | 3.95 | 371,642.50 | -34.11 | -23.40 | -40.73 | -26.37 | -- | -- | -126.34 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
Data as of Nov 25 2024. Currency figures normalised to Rani Therapeutics Holdings Inc's reporting currency: US Dollar USD
13.69%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 30 Sep 2024 | 2.57m | 7.97% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 705.93k | 2.19% |
| USAA Investment Services Co.as of 30 Sep 2024 | 302.74k | 0.94% |
| Stifel Nicolaus & Co., Inc. (Investment Management)as of 30 Sep 2024 | 269.77k | 0.84% |
| Geode Capital Management LLCas of 30 Sep 2024 | 172.26k | 0.53% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 105.63k | 0.33% |
| Luther King Capital Management Corp.as of 30 Sep 2024 | 81.13k | 0.25% |
| Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 30 Sep 2024 | 74.43k | 0.23% |
| Bridgeway Capital Management LLCas of 30 Sep 2024 | 71.50k | 0.22% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 63.58k | 0.20% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
